VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium.

Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.